CHARLOTTESVILLE, Va., Nov. 21, 2024 (GLOBE NEWSWIRE) — TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages.
Firm Remains Focused on Partnering with Healthcare Business Owners on Control Growth Transactions
WASHINGTON, Nov. 20, 2024 /PRNewswire-PRWeb/ — NaviMed Capital, a Washington, DC-based private equity firm focused exclusively on the healthcare industry, today announced the closing of its third fund, NaviMed Partners III (“Fund III”). The substantially oversubscribed new fund closed at its hard cap of $450 million of commitments. With the new fund, NaviMed now manages more than $850 million of capital commitments.
NaviMed will continue to focus on control investments in fast growing lower middle-market healthcare companies. The firm specializes in acquiring businesses that provide business process outsourcing services to hospitals and other healthcare providers, health insurers, and the pharmaceutical and medical device industries. NaviMed seeks to invest in profitable private companies with up to $10 million of EBITDA and double-digit annual revenue growth.
POTOMAC, Md.–(BUSINESS WIRE)–Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the significant, undisclosed round will support development of the company’s novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions.
GLP-1-based therapies have proven efficacy in treating obesity and associated co-morbidities, but come with significant drawbacks. These include up to 40% of weight loss from muscle mass reduction, potentially leading to long-term side effects, especially in elderly patients. This limitation, in addition to tolerability issues, reduces the long-term utility of these agents.
There are several keys to successful entrepreneurship—a great idea that solves a unique problem, the willingness to take risks, leadership skills, networking, and, of course, capital. The last element listed can be especially challenging for those without significant savings, investment from wealthy family members, or generational wealth, says Graham Dodge, vice president, Venture Development at TEDCO, (Maryland Technology Development Corporation), an independent instrumentality of the State of Maryland to facilitate the creation of businesses and support their growth in all regions of the State.
REHOVOT, Israel and WASHINGTON, Nov. 19, 2024 (GLOBE NEWSWIRE) — Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it is joining the Johnson & Johnson Innovation – JLABS (JLABS) site in Washington, D.C. As part of JLABS @ Washington, DC, Biolojic Design will be able to access lab space, resources and collaboration opportunities as the company establishes a presence in the United States.
Showcased via a joint presentation at SC24, the application demonstrates the seamless integration of the core workflow behind several hybrid quantum-classical approaches to calculate the specific properties of a molecule’s electronic structure. These approaches have potential relevance in many chemistry-focused commercial applications, such as identifying how drug molecules might interact with specific proteins in the human body. The achievement captures IonQ’s interest in developing solutions that combine the benefits of quantum processing units (QPUs) with the accelerated, heterogeneous computing capabilities of the NVIDIA CUDA-Q platform.
The NIH Office of Technology Transfer is recruiting for a Deputy Director (GS-15 level) to lead its License Compliance and Administration Unit. This critical role involves managing NIH’s large and diverse invention license portfolio.
Position Details:
Title: Supervisory Technology Transfer Specialist (GS 601-15)
Location: Montgomery County, MD
Open Date: Monday, November 18, 2024
Close Date: Friday, November 22, 2024
This is an All-Sources announcement with two application pathways:
? Current or former USG employees: https://lnkd.in/eYJuHMpV
? U.S. citizens: https://lnkd.in/etYHqykM
Don’t miss this chance to join a dynamic team and make an impact on technology transfer at NIH!
By BHI EIR Anna Zornosa – On October 24th, Arpa-H announced the 23 winners of its “Sprint for Women’s Health” initiative. I’ve had a chance now to read the announcement carefully and assess the impact. Having done so, I can share that I’m impressed, grateful, and certain that decades from now we’ll look back on the Biden Administration’s accomplishments and count progress on #womenshealth as chief among them.
But the question of whether the $110 M in grants awarded last month will make an impact won’t take that long to determine. The unique thing about the ARPA-H mission and methodology is that it allows for some big bets with short time-lines. Awards were divided into two tracks: “Sparkplug” projects representing high potential research with grants of about $3 M; and “Launchpad” projects where initiatives already at or near prototype get $10 M in funding to take a product to market. And the expectation is that Launchpad efforts, if successful, will be launched in two years.
Join us for an insightful episode of BioTalk as Rich Bendis speaks with Eric Mayton, CEO of Cerillo, one of the recent winners at the Crab Trap competition during the 10th Annual BioHealth Capital Region Week. Cerillo, based in Charlottesville, VA, is making waves in microbiome research and biological product development with its innovative tools designed to tackle variability challenges and enhance data collection efficiency.
In this episode, Eric shares Cerillo’s mission to combat Eroom’s Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo’s co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.
Listen via your favorite podcast platform:
Apple – https://apple.co/3Cw22DT
Spotify – https://spoti.fi/40QSuxu
Amazon Music – https://amzn.to/40MEIvU
Tunein – https://bit.ly/4eyK01b
WASHINGTON, D.C., (November 14, 2024) – Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction by over 77% following treatment with investigational nipocalimab in adult patients with moderate-to-severe Sjögren’s disease (SjD). These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company’s 43 oral and poster presentations at the American College of Rheumatology (ACR) Convergence 2024.
